Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines.

Slides:



Advertisements
Similar presentations
CSO/NGO Consultations Report to IATI Signatories, Partner Countries and Steering Committee Paris, 4 July 2011.
Advertisements

Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
Implementation of TRIPS Flexibilities in National IP Legislation for Strengthening Access to Medicines in Seychelles.
Presented to CSO workshops in Kabwe on 18 July 2014, Livingstone on 28 July 2014 and Lusaka on 27 August 2014.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Medicines Transparency Alliance Presented by Deirdre Dimancesco Department of Essential Medicines and Health Products, WHO at the Technical Briefing Seminar.
USAID Update 2014 Bureau for Global Health Christine Malati, PharmD
Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
FORMATION OF THE GHANA MeTA CIVIL SOCIETY NETWORK : AN OVERVIEW 1 Allotey. C; 2 Ahiabu. R.K.A; 3 Ntoso. R.Y; 4 Azumah. S.K; 5 Andoh.I 1,5. Health Access.
Public Health, Innovation and Intellectual Property Improving access to medicines through local production: Some New Development I P C Meeting, Copenhagen.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
BSP Contraceptive Initiative To broaden sustainable access to quality hormonal contraceptives through a new commercial venture Reproductive Health Supplies.
Medicines Transparency Alliance13/09/ MeTA Uganda Country Overview Public Sector Private Sector Civil Society.
MULTI-STAKEHOLDER COLLABORATION: CAN IT IMPROVE TRANSPARENCY, DISCLOSURE AND ACCESS TO MEDICINES? EXPERIENCES FROM 7 META PILOT COUNTRIES Wilbert Bannenberg.
Wilbert Bannenberg, Technical Director MeTA International Secretariat IACC 14 Bangkok, 13 November 2010 MeTA multi-stakeholder process – a way to improve.
Wilbert Bannenberg SARPAM
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Data Disclosure: An Ongoing Progress Towards Transparency Abeer Rabayah B.Sc Pharmacy -MBA /Marketing MeTA National Coordinator.
Medicines Transparency Alliance03/10/ MeTA Zambia Violet Kabwe MeTA Zambia Consultant.
PRACTICAL GUIDE FOR THE IMPLEMENTATION OF THE AU ROADMAP FOR SHARED RESPONSIBILITY AND GLOBAL SOLIDARITY FOR AIDS, TB AND MALARIA SABELO MBOKAZI -AUC 8.
APEC PTIN Food Safety Activities January 27, 2011.
Contact Monitoring Regional Network (CMKN). Why procurement It is estimated that an effective public procurement system could save as much as 25% of government.
MSF Access Campaign Started in 1999 Rooted in field experience Three Pillars: –Overcoming Barriers –Research and Development for Drugs for Neglected Diseases.
1 Towards a Medicines Transparency Alliance (MeTA) Richard Laing and Ali Cameron with slides prepared by Michael Borowitz, DfID WHO Technical Briefing.
Samia Saad 1, Birgit Kerstens 2, Wilbert Bannenberg 1,2 1 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2 Health Research for Action (HERA),
Advances and Challenges in Family Planning in Nicaragua Contraceptive Security Committee Nicaragua April, 2007.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
Slide 1 Win-Win or Lose-Lose? Why is multi-stakeholder involvement essential? Saul Walker Senior Health Advisor UK Department for International Development.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Medicines Transparency Alliance27/10/ MeTA Ghana Augustina Koduah (Mrs) Country Coordinator.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Objective the aim of this project was directly addressing a major health problem for Jordan by producing a guideline as a pilot in which the strengths.
META PHILIPPINES WORKPLAN : EARLY ACCOMPLISHMENTS IN THE PILOT PHASE.
Adhoc Committee on Health 22 June DISPENSING LICENCE  Have 4 providers for the course 1. Health Science Academy 2. Intec College 3. Medunsa 4.
SARPAM Southern African Regional Programme for Access to Medicines and Diagnostics Presentation to Botswana TRIPS and Access to Medicines workshop 26 March.
Medicines systems: Convergence for access Dr Socorro Escalante WHO Country Office for Viet Nam 1.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Medicines Transparency Alliance Presented by Gilles Forte Department of Essential Medicines and Health Products, WHO On behalf of WHO and HAI Technical.
SOUTHERN AFRICAN REGIONAL PROGRAMME ON ACCESS TO MEDICINES AND DIAGNOSTICS PROCESS & CHALLENGES OF WORKING REGIONALLY IN SOUTHERN AFRICA AARTI PATEL WHO.
Medicines Transparency Alliance18/12/ Country overview MeTA Kyrgyzstan Mariam Djankorozova MeTA Country coordinator.
Vision: A strong and capable civil society, cooperating and responsive to Cambodia’s development challenges Host of the 2nd Global Assembly for CSO Development.
CoST Construction Sector Transparency Initiative (CoST) Bethan Grillo, CoST international secretariat IACC, 1 November 2008.
Trilateral Development Cooperation: How to make it more Effective? Global Partnership for Development Conference New Delhi 13 August 2008 Roger Nellist.
Medicines Transparency Alliance31/01/ MeTA Uganda Jacqueline Idusso Secretariat Coordinator.
GLOBAL FINANCING FACILITY IN SUPPORT OF EVERY WOMAN EVERY CHILD.
Seattle, WA, USA Reproductive Health Supplies Coalition: Reviewing the Strategic Plan Semi-annual Membership Meeting London, April 2007.
Wilbert Bannenberg Technical Director, Intl MeTA Secretariat 28 April 2010, IPC meeting, Copenhagen Medicines Transparency Alliance: improving people’s.
People that Deliver Improving health outcomes by promoting sustainable workforce excellence in health supply chain management A multi-stakeholder, cross-program.
Overview  What is the Global Partnership for Education?  Background on Strategic Plan  GPE’s Proposed Principles and Values  Proposed GPE Strategic.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
UNGGIM – PRIVATE SECTOR NETWORK. AGENDA > OVERVIEW OF PRIVATE SECTOR >PURPOSE AND VISION OF PRIVATE SECTOR NETWORK > STRUCTURE AND TERMS OF REFERENCE.
The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team.
SADC Medicines Database (SMD)
Wilbert Bannenberg SARPAM
Goal 8 Develop a global partnership for development
WHO Medicines Work in Countries: The Kenya Example
A Partnership Model: African Mineral Skills Initiative
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
Dr Sameen Siddiqi, WHO Representative, Iran
Private Sector: Who is Accountable?
UHC2030 Private Sector Constituency –
National Medicines Policies
Presentation transcript:

Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines Transparency Alliance 16/04/20091

The MeTA “model” Goal: increased access to essential medicines Purpose: Test if multi-stakeholder approach increases transparency, governance, efficiency and accountability, and encourages responsible business practices. MeTA12/03/20162

Medicines? 1/3 of the world’s population (2 billion people!) still have no access to good quality, essential medicines Gross inefficiencies in drug supply systems Governments alone cannot provide the service 16/04/2009 3

Transparency? Improving information access, scrutiny and use, in order to support the development of viable, efficient medicines markets and supply systems that benefit all developing country consumers – Transparency = not only disclosure of the price, quality, availability and promotion of medicines – But also how to use the information to identify barriers, and to agree on solutions – Accounting and Accountability

Drug Supply – Transparent? Source: SSDS Inc for the World Bank

Alliance? Global multi-stakeholder alliance – DFID – WHO – World Bank – Private Sector (pharmaceutical Industry, generic and local manufacturers, wholesalers, retailers etc) – Civil Society (public health, transparency, accountability and rights NGOs, grassroots networks, patients/consumer organisations, academia) – Seven MeTA pilot countries (incl. Kyrgyz Republic!)

What does MeTA want to do? Improve transparency and accountability on: – Price – Quality – Availability – Promotion Promote more: – Efficient supply chains – Affordable medicines – Equitable access – Rational use of medicines 16/04/2009 7

7 Pilot Countries … pioneers, leaders, champions and innovators! 16/04/ … pioneers, leaders, champions and innovators!

Country Commitments Establish an effective multi-stakeholder forum Progressive disclosure of data in four areas Quality Regulatory, sourcing, quality assurance, vigilance Availability Supply chain operations, equitable access PriceSupplier, wholesaler, retailer, import taxes, duties, affordability PromotionObjective information,Rational use, good and ethical advertising and promotion 16/04/2009 9

MeTA phase 1: March Sept 2010 MeTA Global launches: – 15 May 2008 London, 21 May 2008 WHO Assembly Activities in all 7 pilot countries – MeTA Secretariat, WHO, World Bank can provide TA – GBP 100,000 / year support – Civil Society Capacity Strengthening Grant for CSO coalition up to GBP 50,000 Global feed-back meeting Feb 2010 External evaluation March 2010 If positive, DFID’s commitment for Phase 2 of MeTA:10 years

Congratulations! Congratulations and best wishes to MeTA Kyrgyzstan and its stakeholders on the launch of the MeTA Project! 16/04/ International MeTA Secretariat

16/04/ More information? Wilbert Bannenberg, Elodie Brandamir, International Secretariat, MeTA website: